Literature DB >> 20039300

In vivo tumor cell rejection induced by NK cell inhibitory receptor blockade: maintained tolerance to normal cells even in the presence of IL-2.

Gustaf Vahlne1, Katja Lindholm, Anders Meier, Stina Wickström, Tadepally Lakshmikanth, Frank Brennan, Michael Wilken, Rikke Nielsen, François Romagné, Nicolai R Wagtmann, Klas Kärre, Maria H Johansson.   

Abstract

Missing-self-reactivity can be mimicked by blocking self-specific inhibitory receptors on NK cells, leading to increased rejection of syngeneic tumor cells. Using a mouse model, we investigated whether Ab-mediated blocking of inhibitory receptors, to a degree where NK cells rejected syngeneic tumor cells, would still allow self-tolerance toward normal syngeneic cells. Ly49C/I inhibitory receptors on C57BL/6 (H-2(b)) NK cells were blocked with F(ab')(2) fragments of the mAb 5E6. Inhibitory receptor blockade in vivo caused rejection of i.v. inoculated fluorescence-labeled syngeneic lymphoma line cells but not of syngeneic spleen cells, BM cells or lymphoblasts. The selective rejection of tumor cells was NK cell-dependent and specifically induced by Ly49C/I blockade. Moreover, selective tumor rejection was maintained after treatment with 5E6 F(ab')(2) for 9 wk, arguing against the induction of NK cell anergy or autoreactivity during this time. Combination therapy using 5E6 F(ab')(2) together with high dose IL-2 treatment further increased lymphoma cell rejection. In addition, combination therapy reduced growth of melanoma cell line tumors established by s.c. inoculation 3 days before start of treatment. Our results demonstrate that inhibitory receptor blockade does not result in attack on normal cells, despite potent reactivity against MHC class I-expressing tumors.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20039300     DOI: 10.1002/eji.200939755

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  15 in total

1.  Targeting KIR Blockade in Multiple Myeloma: Trouble in Checkpoint Paradise?

Authors:  Martin Felices; Jeffrey S Miller
Journal:  Clin Cancer Res       Date:  2016-07-18       Impact factor: 12.531

Review 2.  Therapeutic approaches to enhance natural killer cell cytotoxicity against cancer: the force awakens.

Authors:  Richard W Childs; Mattias Carlsten
Journal:  Nat Rev Drug Discov       Date:  2015-05-22       Impact factor: 84.694

3.  IL15 induces a potent antitumor activity in NK cells isolated from malignant pleural effusions and overcomes the inhibitory effect of pleural fluid.

Authors:  D Croxatto; S Martini; L Chiossone; F Scordamaglia; C F Simonassi; L Moretta; M C Mingari; P Vacca
Journal:  Oncoimmunology       Date:  2017-02-17       Impact factor: 8.110

4.  IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect.

Authors:  Don M Benson; Courtney E Bakan; Shuhong Zhang; Shauna M Collins; Jing Liang; Shivani Srivastava; Craig C Hofmeister; Yvonne Efebera; Pascale Andre; Francois Romagne; Mathieu Bléry; Cécile Bonnafous; Jianying Zhang; David Clever; Michael A Caligiuri; Sherif S Farag
Journal:  Blood       Date:  2011-10-26       Impact factor: 22.113

Review 5.  NK cells and cancer: you can teach innate cells new tricks.

Authors:  Maelig G Morvan; Lewis L Lanier
Journal:  Nat Rev Cancer       Date:  2016-01       Impact factor: 60.716

Review 6.  NK cells: immune cross-talk and therapeutic implications.

Authors:  Anshu Malhotra; Anil Shanker
Journal:  Immunotherapy       Date:  2011-10       Impact factor: 4.196

7.  Cytokine therapy reverses NK cell anergy in MHC-deficient tumors.

Authors:  Michele Ardolino; Camillia S Azimi; Alexandre Iannello; Troy N Trevino; Lucas Horan; Lily Zhang; Weiwen Deng; Aaron M Ring; Suzanne Fischer; K Christopher Garcia; David H Raulet
Journal:  J Clin Invest       Date:  2014-10-20       Impact factor: 14.808

8.  Natural killer cell tolerance persists despite significant reduction of self MHC class I on normal target cells in mice.

Authors:  Petter Brodin; Tadepally Lakshmikanth; Ramit Mehr; Maria H Johansson; Adil Doganay Duru; Adnane Achour; Mali Salmon-Divon; Klas Kärre; Petter Höglund; Sofia Johansson
Journal:  PLoS One       Date:  2010-10-04       Impact factor: 3.240

9.  Contrasting effects of anti-Ly49A due to MHC class I cis binding on NK cell-mediated allogeneic bone marrow cell resistance.

Authors:  Maite Alvarez; Can M Sungur; Erik Ames; Stephen K Anderson; Claire Pomeroy; William J Murphy
Journal:  J Immunol       Date:  2013-06-10       Impact factor: 5.422

Review 10.  NK cell self tolerance, responsiveness and missing self recognition.

Authors:  Nataliya Shifrin; David H Raulet; Michele Ardolino
Journal:  Semin Immunol       Date:  2014-03-12       Impact factor: 11.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.